04-12-2023 05:11 PM | Source: Reuters
India`s SII could resume Covishield shot production as COVID cases rise
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
The Serum Institute of India (SII) could resume production of the Covishield COVID-19 vaccine, a company spokesperson said on Wednesday, as infections rise in the country.
The world's biggest vaccine maker already has a stock of 6 million doses of Covovax, a version of a Novavax vaccine, the spokesperson added. Covishield is a version of an AstraZeneca shot.
Latest News
Insurance Sector Update : Motor drags down overall g...
Sell Gold Below 72700 SL Above 72950 TGT 72400/72100...
Wipro shares nosedived over 9 pc after missed earnin...
Economic Survey links mental health disorders with '...
India's GDP growth for FY25 to surpass Economic Surv...
Evening Roundup : A Daily Report on Bullion Energy &...
FIIs stood as net buyers in equities as per July 22 ...
Union Budget: Experts urge government to remove 18 ...
Poonawalla Fincorp AUM up 52% YoY to Rs 26,972 crore...
Sensex ends lower ahead of Union Budget 2024-25
